The TRAIL ligand is a promising anti-cancer agent that preferentially kills tumor cells without apparent damage to healthy cells. Many cancers exhibit resistance to TRAIL, however, thus limiting its therapeutic potential. According to a new study, small molecules known to block Mcl-1 might represent a suitable means to overcome TRAIL resistance.